AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
5.25
+2.40 (84.21%)
At close: Mar 9, 2026, 4:00 PM EDT
5.03
-0.22 (-4.15%)
After-hours: Mar 9, 2026, 7:59 PM EDT

AN2 Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
14441609185--
Market Cap Growth
326.09%-93.23%229.57%---
Enterprise Value
83.31-42.33502.1188.8500
Last Close Price
5.251.3820.499.53--
PE Ratio
--0.80-7.48-3.42--
PB Ratio
2.400.504.891.94--
P/TBV Ratio
2.620.503.881.53--
P/FCF Ratio
--0.84-11.44-5.53--
P/OCF Ratio
--0.84-11.44-5.53--
EV/EBITDA Ratio
-0.75-7.21-2.10--
EV/EBIT Ratio
-0.75-7.21-2.10--
EV/FCF Ratio
-0.86-9.42-2.66--
Debt / EBITDA Ratio
---0.00--
Debt / FCF Ratio
---0.00--
Net Debt / Equity Ratio
-1.03-1.02-0.86-1.011.240.20
Net Debt / EBITDA Ratio
1.661.471.542.272.710.56
Net Debt / FCF Ratio
2.071.702.012.872.860.76
Quick Ratio
9.038.177.6413.3717.252.79
Current Ratio
9.338.437.8713.7217.702.90
Return on Equity (ROE)
-10.58%-49.69%-58.83%-40.02%-32.54%-80.77%
Return on Assets (ROA)
-46.94%-49.20%-57.72%-50.35%-62.04%-146.65%
Return on Invested Capital (ROIC)
3197.18%-664.34%-798.20%-3065.80%-2052.71%1088.79%
Return on Capital Employed (ROCE)
-52.58%-54.99%-63.28%-53.74%-66.69%-175.18%
Earnings Yield
-23.40%-124.64%-13.37%-29.28%--
FCF Yield
--119.30%-8.74%-18.10%--
Buyback Yield / Dilution
-0.45%-0.90%-13.95%-38.05%--
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q